MeSH D006084 - graft rejection
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Mycophenolate mofetil | Mycophenolate mofetil Teva | 2008-02-21 | |||
| Mycophenolate mofetil | Myfenax | 2008-02-21 | ||||
| Roche | Mycophenolate mofetil | CellCept | 1996-02-14 | $491.925 M | Q4/22-Q3/23 | |
| Daclizumab | Zenapax | 1999-02-26 | ||||
| Novartis | Basiliximab | Simulect | 1998-10-09 | |||
| Pfizer | Sirolimus | Rapamune | 2001-03-13 | $170 M | Y2016 | |
| Bristol Myers Squibb | Belatacept | Nulojix | 2011-06-17 | $26 M | Y2013 | |
| Astellas Pharma | Tacrolimus | Advagraf | 2007-04-23 | |||
| Tacrolimus | Modigraf | 2009-05-15 | ||||
| Chiesi Farmaceutici | Tacrolimus | Envarsus | 2014-07-18 | |||
| Nova Laboratories | Azathioprine | Jayempi | 2021-06-21 |
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
63%12/19
Phase 3
87%13/15
Approved: 6Overall Success rate: 55%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use